-+ 0.00%
-+ 0.00%
-+ 0.00%
Yakkang Biotech announced that the company plans to acquire 80% of the shares of Nanjing Baimai Biotechnology Co., Ltd. held by Jiang Yuwei, Henghui Pharmaceutical Group Co., Ltd. and Harbin Yuheng Pharmaceutical Co., Ltd. in cash at a transaction price of RMB 312 million. The transaction was reviewed and approved by the third meeting of the third board of directors of the company, and there is no need to submit it to the shareholders' meeting for review; after the transaction is completed, Baimai Biotech will become the company's holding subsidiary and included in the scope of the consolidated statement. Jiang Yuwei promised that the cumulative net profit of Baimai Biotech after deducting non-recurring profit and loss in the 2026, 2027, and 2028 consolidated statements will not be less than RMB 100 million. The transaction still needs to meet the entry into force and delivery conditions agreed upon in the agreement. There is a risk that performance promises will not be fulfilled, acquisition integration and synergy effects will fall short of expectations, and goodwill impairment.
Share
Listen to the news
Yakkang Biotech announced that the company plans to acquire 80% of the shares of Nanjing Baimai Biotechnology Co., Ltd. held by Jiang Yuwei, Henghui Pharmaceutical Group Co., Ltd. and Harbin Yuheng Pharmaceutical Co., Ltd. in cash at a transaction price of RMB 312 million. The transaction was reviewed and approved by the third meeting of the third board of directors of the company, and there is no need to submit it to the shareholders' meeting for review; after the transaction is completed, Baimai Biotech will become the company's holding subsidiary and included in the scope of the consolidated statement. Jiang Yuwei promised that the cumulative net profit of Baimai Biotech after deducting non-recurring profit and loss in the 2026, 2027, and 2028 consolidated statements will not be less than RMB 100 million. The transaction still needs to meet the entry into force and delivery conditions agreed upon in the agreement. There is a risk that performance promises will not be fulfilled, acquisition integration and synergy effects will fall short of expectations, and goodwill impairment.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending